Bruno Maranda is a Medical geneticist at the Center Hospitalier Universitaire de Sherbrooke (CHUS) and associate professor in the Department of Pediatrics at the University of Sherbrooke, Dr. Maranda has a general genetics practice focused on inborn errors of metabolism. He is also involved in clinical trials and clinical research on lysosomal storage diseases, phenylketonuria, cancer, and neurotransmitter disorders. Dr. Maranda is also the Founder and Chairman of MendeliKABS , a specialty pharmaceutical company marketing a generic version of an orphan drug, Nitisinone, in over 40 countries.